Phathom Pharmaceuticals (PHAT) to Post Quarterly Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is projected to post its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $72.70 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:00 AM ET.

Phathom Pharmaceuticals Stock Performance

Shares of NASDAQ PHAT traded up $0.04 during mid-day trading on Wednesday, reaching $11.70. 109,143 shares of the company traded hands, compared to its average volume of 1,160,943. The company’s fifty day moving average is $10.88 and its two-hundred day moving average is $11.79. Phathom Pharmaceuticals has a fifty-two week low of $8.02 and a fifty-two week high of $18.31. The stock has a market cap of $933.43 million, a PE ratio of -5.52 and a beta of 0.49.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of PHAT. Millennium Management LLC raised its stake in Phathom Pharmaceuticals by 125.8% during the 3rd quarter. Millennium Management LLC now owns 5,081,451 shares of the company’s stock valued at $59,809,000 after purchasing an additional 2,830,954 shares during the last quarter. Moore Capital Management LP acquired a new position in shares of Phathom Pharmaceuticals during the second quarter valued at about $5,754,000. Invesco Ltd. lifted its stake in shares of Phathom Pharmaceuticals by 13.4% in the second quarter. Invesco Ltd. now owns 4,140,072 shares of the company’s stock valued at $39,703,000 after buying an additional 489,260 shares during the period. Vanguard Group Inc. grew its position in Phathom Pharmaceuticals by 15.4% during the third quarter. Vanguard Group Inc. now owns 3,215,572 shares of the company’s stock worth $37,847,000 after buying an additional 428,261 shares in the last quarter. Finally, SummitTX Capital L.P. bought a new position in Phathom Pharmaceuticals during the third quarter valued at about $4,543,000. Institutional investors and hedge funds own 99.01% of the company’s stock.

Analyst Upgrades and Downgrades

PHAT has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $26.00 price target on shares of Phathom Pharmaceuticals in a report on Wednesday, June 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.50.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.